Institut Za Virusologiju, Vakcine I Serume Torlak is based in Serbia. The head office is in Belgrade. It operates in the Outpatient Care Centers sector. The company was established on January 11, 1995. 227 (2019) employees currently work for Institut Za Virusologiju, Vakcine I Serume Torlak. From the latest financial highlights, Institut Za Virusologiju, Vakcine I Serume Torlak reported a net sales revenue drop of 51.76% in 2022. Its’ total assets recorded a negative growth of 17.13%. The net profit margin of Institut Za Virusologiju, Vakcine I Serume Torlak decreased by 8.15% in 2022.

Headquarters
Vojvode Stepe 458
Belgrade; Belgrade;

Contact Details: Purchase the Institut Za Virusologiju, Vakcine I Serume Torlak report to view the information.

Website: http://www.torlak.rs

Basic Information

Total Employees:

Purchase the Institut Za Virusologiju, Vakcine I Serume Torlak report to view the information.

Registered Capital:

Purchase the Institut Za Virusologiju, Vakcine I Serume Torlak report to view the information.

Financial Auditors:

Purchase the Institut Za Virusologiju, Vakcine I Serume Torlak report to view the information.

Incorporation Date:

January 11, 1995

Key Executives

Purchase this report to view the information.

Acting Director

Ownership Details

Purchase this report to view the information.

100%

Subsidiaries

Biomedicinski Centar Instituta Torlak D.O.O.Beograd - U Likvidaciji

100%

Company Performance

Financial values in the chart are available after Institut Za Virusologiju, Vakcine I Serume Torlak report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.

Net sales revenue

-51.76%▼

Total operating revenue

-61.5%▼

Operating Profit/Loss (EBIT)

N/A

EBITDA

N/A

Net Profit/Loss for the Period

-95.98%▼

Total Assets

-17.13%▼

Total Equity

0.64%▲

Operating Profit Margin (ROS)

N/A

Net Profit Margin

-8.15%▼

Return on Equity (ROE)

-15.26%▼

Quick Ratio

0.68%▲

Cash Ratio

0.26%▲

Institut Za Virusologiju, Vakcine I Serume Torlak (Serbia)